Publications by authors named "A Lacko"

Introduction: Breast cancer (BC) is among the most frequently diagnosed malignant tumours in females. The optimal treatment of early HR+, HER2-, and lymph node-negative (N0) BC remains challenging. Since individual assessment of recurrence risk and expected benefits from adjuvant chemotherapy (CT) based on clinicopathological features alone appear inadequate, gene expression profiling tests have been developed.

View Article and Find Full Text PDF
Article Synopsis
  • The NATALEE trial evaluated the effectiveness of ribociclib in combination with nonsteroidal aromatase inhibitors (NSAI) compared to NSAI alone over three years for treating HR+/HER2- early breast cancer patients.
  • The study involved 5,101 patients who were randomized to receive either ribociclib plus NSAI or NSAI alone, with the primary focus on invasive disease-free survival (iDFS).
  • Results showed that ribociclib plus NSAI significantly improved iDFS, with 90.7% of patients remaining disease-free compared to 87.6% for those on NSAI alone, while safety profiles remained consistent with no new safety concerns.
View Article and Find Full Text PDF

Introduction: Sacituzumab govitecan (SG) is approved for patients with previously treated metastatic or locally advanced triple-negative breast cancer (TNBC), as per the ASCENT trial results. Real-world studies (RWSs) cover more diverse patients than clinical trials, offering crucial data for healthcare policies. This study aimed to investigate the safety and efficacy of SG in real-world Polish patients with previously treated metastatic TNBC.

View Article and Find Full Text PDF

Diabetic kidney disease (DKD) is a devastating kidney disease and lacks effective therapeutic interventions. The present study was aimed to determine whether reconstituted high-density lipoprotein (rHDL) ameliorated renal injury in eNOS dbdb mice, a mouse model of DKD. Three groups of mice, wild type C57BLKS/J (non-diabetes), eNOS dbdb (diabetes), and eNOS dbdb treated with rHDL (diabetes+rHDL) with both males and females were used.

View Article and Find Full Text PDF

Cytotoxic activity has been reported for the xanthone α-mangostin (AMN) against Glioblastoma multiforme (GBM), an aggressive malignant brain cancer with a poor prognosis. Recognizing that AMN's high degree of hydrophobicity is likely to limit its systemic administration, we formulated AMN using reconstituted high-density lipoprotein (rHDL) nanoparticles. The photophysical characteristics of the formulation, including fluorescence lifetime and steady-state anisotropy, indicated that AMN was successfully incorporated into the rHDL nanoparticles.

View Article and Find Full Text PDF